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Objective: To investigate chest wall pain in patients with
peripheral early stage lung cancer treated with stereo-
tactic ablative radiotherapy (SABR), and to identify
factors predictive of Common Terminology Criteria of
Adverse Events Grade 21chest wall pain.
Methods: Patients who received 55Gy in five fractions
were included. A chest wall structure was retrospectively
defined on planning scans, and chest wall dosimetry and
tumour-related factors recorded. Logistic regression was
performed to identify factors predictive of $Grade 2
chest wall pain.
Results: 182 patients and 187 tumours were included.
There were 20 (10.9%) episodes of $Grade 2 chest wall
pain. Multivariate logistic regression demonstrated that
the maximum dose received by 1 cm3 of chest wall
(Dmax1 cm
3) and tumour size were significant predictors
of $Grade 2 chest wall pain [Dmax1 cm
3 odds ratio : 1.104,
95% confidence interval : 1.012–1.204, p50.025; tumour
size (mm) odds ratio : 1.080, 95% confidence interval :
1.026–1.136, p50.003]. This model was an adequate fit to
the data (Hosmer and Lemeshow test non-significant) and
a fair discriminator for chest wall pain (area under receiver-
operating characteristic curve: 0.74). Using the multivariate
logistic regression model, parameters for Dmax1cm
3 are
provided, which predict ,10% and ,20% risks of $Grade 2
chest wall pain for different tumour sizes.
Conclusion: Grade 21chest wall pain is an uncommon side
effect of lung SABR. Larger tumour size and increasing
Dmax1cm
3 are significant predictors of $Grade 2 chest wall
pain. When planning lung SABR, it is prudent to try to avoid
hot volumes in the chest wall, particularly for larger tumours.
Advances in knowledge: This article demonstrates that
Grade 2 or greater chest wall pain following lung SABR is
more common when the tumour is larger in size and the
Dmax1 cm
3 of the chest wall is higher. When planning lung
SABR, the risk of chest wall pain may be reduced if
maximum doses are minimized, particularly for larger
tumours.
INTRODUCTION
Stereotactic ablative radiotherapy (SABR) in patients with early-
stage peripheral lung cancer is an increasingly adopted treat-
ment option for patients who are considered unsuitable for
surgical intervention.1 Despite the high dose per fraction, SABR
is usually well tolerated.1–3 Fatigue, pulmonary toxicity, chest
wall toxicity and brachial plexopathy are reported side effects.2–7
Chest wall toxicity includes skin reactions (erythema, ulceration
and ﬁbrosis), chest wall pain and rib fracture.5,8–10 The duration
of chest wall pain varies from transient to several weeks or
longer and usually occurs more than 6 months after SABR.5,11
This report details chest wall pain following lung SABR in
a cohort of 182 patients and attempts to identify factors
which may contribute to the development of chest wall
pain. Patients with tumours adjacent to the chest wall, who
therefore received a SABR dose of 55Gy in ﬁve fractions,
were included in the analysis.
METHODS AND MATERIALS
This was a retrospective review of clinically gathered data.
Patients, eligibility for stereotactic ablative
radiotherapy and treatment
Medically inoperable patients treated with lung SABR
at St James’s Institute of Oncology between January 2009
and December 2012 were included. Patients were treated
using a risk-adapted SABR protocol.
Patients were eligible for SABR provided the tumour was:12
(1) peripheral (i.e. out with a 2-cm safety zone around the
central, lobar and segmental airways)
(2) histologically proven non-small cell lung cancer or consid-
ered malignant based on ﬂudeoxyglucose positron emission
tomography (PET) positivity and/or growth on sequential
CT scans
(3) #5 cm
(4) node negative on PET 1/2 endobronchial ultrasound-
guided biopsy
(5) non-metastatic based on ﬂudeoxyglucose PET scanning.
Patients were immobilized with a custom-made Vac-Lok™ bag
(Civco Medical Solutions, Coralville, IA) using a standard wing
board arm support system in the supine position. If the wing
board was unsuitable owing to tumour position, then a ther-
moplastic shell (Orﬁt Industries, Wijnegem, Belgium) was used.
A multislice, helical, respiration-correlated CT (four-
dimensional CT) was performed to determine patient-speciﬁc
motion margins using a Siemens Somatom® scanner (Siemens
AG, Erlangen, Germany) connected to a commercially available
respiratory sensor (AZ-733V; Anzai Medical, Tokyo, Japan).
The gross tumour volume (GTV) was contoured on three of the
respiratory phases [the mid-ventilation position (typically 40%
exhale), 0% exhalation and 100% exhalation], and an ITV
(internal target volume) was generated which encompassed all
three GTVs. All other four-dimensional CT data sets were
reviewed to check that the ITV encompassed the tumour in all
respiratory phases, and if necessary, the GTV was adapted to
include any inadequately encompassed tumour.12 The ﬁnal ITV
therefore encompassed the GTV throughout the whole re-
spiratory cycle. No margin was added for the clinical target
volume, as is standard in lung SABR practice.12,13 A 5-mm
isotropic margin was added to the ITV to create the planning
target volume PTV as is recommended when using daily online
image guidance using cone-beam CT,12,13 and as has been found
to be adequate based on local audit. The Advantage Workstation
(GE Healthcare, Waukesha, WI) was used for contouring
purposes.
Treatment planning was performed using CMS Xio (Eletka AB,
Stockholm, Sweden). Coplanar or non-coplanar ﬁeld arrange-
ments and 6-MV photons were used. In the majority of cases,
treatment was prescribed to the 80% isodose. Organ at risk and
conformity constraints were as per the UK SABR consortium
guidelines.12 Three dosing schedules were used depending on
tumour location: 54Gy in three fractions (for tumours away
from airways and not adjacent to the chest wall), 55Gy in ﬁve
fractions (for tumours adjacent to the chest wall) and 60Gy in
eight fractions (for tumours close to the mediastinum and air-
ways or brachial plexus). Although a speciﬁc fractionation
schedule is used for tumours in close proximity to the chest wall,
no speciﬁc dosimetric chest wall constraints are employed for
SABR planning. As above, daily online image guidance was
performed using cone-beam CT and a tolerance of ,3mm.12
Only tumours prescribed 55Gy in ﬁve fractions were included in
this analysis as this dose fractionation is used for tumours in
closest proximity to the chest wall. By including only one dose
fractionation schedule, this avoids the need for biologically
equivalent dose conversion (and therefore avoids the in-
troduction of uncertainties in the alpha/beta ratios for the dif-
ferent tissues of the chest wall and uncertainties regarding the
use of the linear-quadratic model for dose conversions when
using high doses per fraction).14
Response assessment and follow-up
Patients were routinely assessed during treatment by therapeutic
radiographers before each fraction, then by an oncologist (MS,
KC, RTor KF) at 6 weeks and 12 weeks following completion of
treatment and then 3 monthly for the ﬁrst 2 years, and 6
monthly for 3–5 years. Chest X-ray was performed at each pa-
tient visit and CT scanning was performed every 6 months
for 5 years.
Chest wall pain was graded according to the Common Termi-
nology Criteria for Adverse Events (CTCAE) v. 3. Asymptomatic
rib fractures were not considered in the analysis.
Definition of the chest wall and dosimetry
The chest wall, including the bone and soft tissue (parietal
pleura and intercostal muscles) in the treated hemithorax, was
contoured retrospectively on the original treatment plans.
The chest wall structure was created as follows:
Chest wall5 ðlung1 3 cm isotropicmarginÞ
 ½lung1 ðpericardium1marginÞ
The margin around the pericardium was 0 cm superiorly, an-
teriorly and laterally, 2 cm inferiorly and 4 cm posteriorly. The
resulting contour was then edited to exclude any remaining
mediastinum and vertebral bodies (Figure 1).
Figure 1. Example of lung stereotactic ablative radiotherapy
plan showing a stage T1 left-sided lung tumour in close
proximity to the chest wall. The chest wall structure which
was used in the analysis is highlighted in magenta. A dose of
55Gy is prescribed to the 80% isodose.
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For each plan, the chest wall mean dose (Dmean), the maximum
dose received by 1 cm3 (Dmax1 cm
3) of the chest wall and the
volume of chest wall receiving 50Gy or more (V50), 30Gy or
more (V30) and 10Gy or more (V10) were recorded.
For every patient, the same experienced radiation oncologist (EK)
measured the shortest distance between the edge of the tumour
and the chest wall (mm) using the lung windows setting. Maxi-
mum tumour diameter was recorded from the diagnostic imaging
reports, and a radiologist in the multidisciplinary meeting reviewed
all imaging prior to SABR.
Data analysis
Overall survival, time to relapse (death not considered an event
unless from lung cancer) and $Grade 2 chest wall pain-free
survival were calculated from the ﬁrst day of radiotherapy
treatment using Kaplan–Meier analysis. In cases of patients with
more than one tumour who received sequential SABR treat-
ments, overall survival statistics were calculated from the treat-
ment start date for the ﬁrst lesion.
Univariate and multivariate binary logistic regression were
performed using backwards elimination using likelihood ra-
tios in order to determine which factors predicted $Grade 2
chest wall pain. The factors included in the analysis were:
patient age, gender, minimum chest wall to tumour distance,
tumour size, chest wall Dmean, chest wall Dmax1 cm
3 (to reﬂect
a near maximum dose) and chest wall V50, V30 and V10 to
reﬂect volumes of chest wall receiving high, medium and
low doses.
Since chest wall pain may develop over time, consideration was
given to assessing the risk of $Grade 2 chest wall pain using
a Cox regression model in addition to a logistic regression
analysis. As the event of importance was whether or not chest
wall pain occurred, and the exact time at which chest wall pain
developed was of less importance, it was decided to use a logistic
regression analysis alone.
A p-value of, 0.05 was considered statistically signiﬁcant. Sta-
tistical analyses were performed using SPSS® v. 21 (IBM Corp.,
New York, NY; formerly SPSS® Inc., Chicago, IL). Goodness of
ﬁt was assessed using the Hosmer and Lemeshow test, and the
discrimination of the model was assessed using the area under
the receiver-operating characteristic (ROC) curve.15
The ﬁnal logistic regression model was used to determine some
clinically useful parameters to limit the risk of $Grade 2 chest
wall pain.
RESULTS
In total, 187 tumours were irradiated using a schedule of 55Gy
in ﬁve fractions in 182 patients. 3 patients had 2 lesions treated
simultaneously and 2 patients had 2 lesions treated sequentially
(thus, 184 treatment episodes in total). Median follow-up was
21.0 months (range: 0.3–45 months). Baseline characteristics are
summarized in Table 1. At the time of analysis, there had been
63 deaths and 27 episodes of cancer relapse, including 6 patients
who developed new primary lung tumours. In total, there were
ﬁve episodes of local relapse (2.7%), two of which were cases of
isolated local relapse and three of which were associated with
Table 1. Baseline characteristics
Characteristic
Age [median (interquartile range)] (years) 75 (69–81)
Male : female (%) 57 : 43
Tumour diameter [median
(interquartile range)]
20mm (16–28mm)
Histological diagnosis (%) 39% (n5 72)
Positron emission tomography standardized
uptake value [median (interquartile range)]
7.9 (4.8–11.9)
Minimum tumour-to-chest wall distance
[median (interquartile range)]
0 (0–5.4mm)
Figure 2. Crude number of episodes of chest wall pain at different time points.
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nodal (two patients) or distant (one patient) relapse. In total,
6 (3.3%) patients developed isolated nodal relapse and 11 patients
developed metastatic disease with or without locoregional re-
currence (6.0%, and including 1 patient, already mentioned
above, who experienced local recurrence). Overall survival was
80.0%, 59.5% and 45.6% at 1, 2 and 3 years, respectively. Me-
dian overall survival was 29 months. The disease relapse-free
proportion (including patients with new primary tumours) was
90.1%, 77.8% and 69.6% at 1, 2 and 3 years, respectively.
The crude number of chest wall pain episodes at different time
points is summarized in Figure 2. For a total of 184 treatment
episodes, a total of 49 (26.7%) patients experienced chest wall
pain of any grade. Chest pain of any grade was reported at only 1
visit in 26 patients, on 2 consecutive visits (i.e. persisting more
than 3 months) in 11 patients and on at least 3 consecutive visits
(i.e. persisting more than 6 months) in 10 patients. Non-
consecutive episodes of chest wall pain occured in 12 patients (i.e. 2
episodes of pain occurred with at least 1 pain-free visit in
between). In total, 20 (10.9%) patients experienced Grade 2 or 3
chest pain. In those patients who experienced $Grade 2 chest
wall pain, the median time to onset was 9 months (range 0–
24 months). Grade 2 or greater chest wall pain-free survival was
92.0% and 89.3% at 1 and 2 years, respectively. Grade 3 chest
wall pain occurred in 5 (2.7%) patients only, and there were no
Grade 4 pain events. None of the patients who experienced local
relapse reported chest wall pain, and so local recurrence with
associated ingrowth into the chest wall did not account for any
of the episodes of chest wall pain described above.
Univariate analysis identiﬁed that the chest wall Dmean,
Dmax1 cm
3 and V50, V30 and V10 were statistically signiﬁcant
predictors of $Grade 2 chest wall pain. In addition, tumour size
was found to be signiﬁcant (Table 2). On multivariate analysis,
only chest wall Dmax1 cm
3 and tumour size remained in the ﬁnal
model (Table 2). The ﬁnal model was non-signiﬁcant using
the Hosmer and Lemeshow test (p5 0.380), thus suggesting that
the ﬁnal model is an adequate ﬁt for the data.15 The area
under the ROC curve for the ﬁnal model was 0.74 (95% con-
ﬁdence interval 0.634–0.845), suggesting that the discrimination
of the model was fair.15
Using the multivariate logistic regression model, based on dif-
ferent tumour sizes, parameters for Dmax1 cm
3 were calculated
which limit the predicted risk of $Grade 2 chest wall pain
to, 10% and , 20% (Table 3). For tumours up to 10mm,
despite the dose heterogeneity that accompanies SABR, it is
unlikely that the chest wall will receive doses high enough to
result in a 10% risk of $Grade 2 chest wall pain. For tumours
up to 20mm, it is unlikely that the chest wall will receive doses
high enough to result in a 20% risk of $Grade 2 chest wall
toxicity.
DISCUSSION
Chest wall pain in association with SABR is more common for
lesions in close proximity to the chest wall.11,16 Symptoms may
develop without obvious injury or may result from rib fracture,
Table 2. Univariate and multivariate logistic regression for $Grade 2 chest wall pain
Factor p-value Odds ratio 95% confidence interval
Univariate analysis
Minimum tumour-to-chest wall distance (mm) 0.058 0.842 0.704–1.006
Chest wall Dmean 0.001 2.104 1.335–3.315
Chest wall Dmax1 cm
3 0.019 1.103 1.016–1.197
Chest wall V50 0.003 1.063 1.021–1.108
Chest wall V30 , 0.001 1.031 1.015–1.047
Chest wall V10 0.004 1.006 1.002–1.010
Tumour size (mm) 0.002 1.082 1.030–1.136
Age 0.269 0.971 0.920–1.023
Gender 0.867 1.083 0.426–2.754
Multivariate analysis
Chest wall Dmax1 cm
3 0.025 1.104 1.012–1.204
Tumour size (mm) 0.003 1.080 1.026–1.136
Table 3. Parameters to limit predicted risk of $Grade 2 chest
wall toxicity depending on tumour size based on multivariate
logistic regression model
Tumour
size (mm)
Dmax1 cm
3 to limit
predicted risk
to, 10% (Gy)
Dmax1 cm
3 to limit
predicted risk
to, 20% (Gy)
#10mm 71.5 80.0
11–20mm 64.0 72.0
21–30mm 56.0 64.0
31–40mm 48.0 56.5
41–50mm 40.0 48.0
Dmax 1 cm
3 maximum dose received by 1 cm3 of chest wall.
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nerve damage or skin reaction (erythema, ulceration and
ﬁbrosis).5,8–10 Equally, rib fractures may occur in association with
SABR but without symptoms.17,18 Chest wall pain syndrome is
characterized by positional pain that can be pleuritic and is often
worsened by activity and can range from mild to severe.19 The
process which underlies SABR-associated chest wall pain is not
fully understood. Cortical thinning in association with chest wall
pain has been observed,20 and peripheral intercostal nerve
injury10,21 and osteoblastic remodelling of weakened bone in
association with inﬂammation are proposed mechanisms.19
We investigated chest wall pain in patients receiving 55Gy in ﬁve
fractions as this dose and fractionation is used speciﬁcally for
patients with tumours adjacent to the chest wall. Chest wall pain
of any grade was observed in 27% of patients, while $Grade 2
pain was infrequent, affecting 11% of patients. Although a range
of frequencies is reported in the literature, pain of $Grade 2 is
generally uncommon. We investigated factors which might
predict $Grade 2 chest wall pain. Univariate analysis identiﬁed
tumour size, chest wall Dmean, Dmax1 cm
3 and V50, V30 and V10
as signiﬁcant predictors of $Grade 2 chest wall pain. It is
expected that V50, V30 and V10 are closely correlated and so the
signiﬁcance of all three parameters in the univariate analysis
should not be overinterpreted. Multivariate logistic regression
identiﬁed tumour size and Dmax1 cm
3 as signiﬁcant predicators
of chest wall pain. Parameters were determined for Dmax1 cm
3
for different tumour sizes, below which the predicted risk of
$Grade 2 chest wall pain is, 10% and , 20%. Our ﬁnal model
was an adequate ﬁt to the data and the discrimination of the
model was fair (area under the ROC curve: 0.74). Often, little is
reported regarding the goodness of ﬁt of logistic regression
models for chest wall pain in the existing literature,9,10,16 and so
it is not possible to comment in detail on the ﬁt of our model in
comparison with other studies.
A small number of studies have previously deﬁned patient-, tu-
mour- and treatment-related factors associated with chest wall
pain after lung SABR (Table 4). A variety of analysis techniques
have been employed and a variety factors have been examined,
thus making it challenging to draw deﬁnitive conclusions re-
garding the most important factors in predicting chest wall pain.
Most studies include patients with primary non-small cell lung
cancer as well as oligometastatic disease to the lung or liver.
Furthermore, a range of dose and fractionation schedules are
often evaluated within the same study. In this present study, we
describe outcomes in relation to 187 SABR treatments for pri-
mary lung cancer (including histologically unproven disease), all
prescribed 55Gy in ﬁve fractions. This is the only study to eval-
uate this schedule in isolation. By evaluating only one schedule,
we have avoided introducing the uncertainties which can result
from different fraction sizes and equivalent dose calculations,
particularly in the setting of large dose per fraction treatments
where the reliability of the linear-quadratic model is debated.14
The chest wall was contoured in a similar way to Dunlap et al5
potentially allowing meaningful comparisons between results.
Using a different modelling process to that used in this present
study, Dunlap et al5 found V30 to be the most useful predictor of
severe chest wall pain or rib fracture. We also found the chestT
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wall V30 to be a signiﬁcant predictor of$Grade 2 chest wall pain
on univariate analysis, but found Dmax1 cm
3 and tumour size to
be the only signiﬁcant factors on multivariate analysis, meaning
that the predictive effect of V30 is diminished when these factors
are taken into account. These factors were not included in the
Dunlap et al analysis. V30 has also been found to be important in
other studies examining SABR-associated chest wall pain, although
there is variation in how these analyses were performed.9,10,21–23
As above, we observed that the maximum chest wall dose (eval-
uated as Dmax1 cm
3) was a signiﬁcant predictor in the risk of chest
wall pain. Similarly, Andolino et al11 and Taremi et al24 found
maximum doses (point dose and Dmax 0.5 cm
3, respectively) to be
important in the development of chest wall pain.
Bongers et al25 in a study of 500 patients, demonstrated that larger
treatment volumes and shorter tumour-to-chest wall distances
were related to chest wall pain. Similarly, Stephans et al10 con-
cluded that tumour size correlated with late chest wall toxicity.
This present study also demonstrated that tumour size was a sig-
niﬁcant predictor of chest wall pain. It may be that tumour-to-
chest wall distance was not identiﬁed as a signiﬁcant predictor of
chest wall pain since all the tumours in this analysis were close to
the chest wall, and more distant tumours (which would have been
prescribed 54Gy in three fractions) were not included.
Some studies have investigated patient-related factors which
may contribute to the risk of chest wall pain: body mass in-
dex, connective tissues diseases and diabetes mellitus have
been shown to be important.9,16,26 Our study is limited in
that we did not have sufﬁcient information to include these in
the analysis, and it may be that the addition of these factors
would improve the goodness of ﬁt and utility of our model.
Indeed, Woody et al26 produced a multivariate model which
included dosimetric information (modiﬁed equivalent uni-
form dose) and body mass index. The area under the ROC
curve was 0.83, and so the inclusion of this patient-related
factor resulted in a more discriminating model than we de-
scribe here.
The median time to the onset of chest wall pain is generally
6 months or more after SABR.5,11,16 In this present study,
20 patients had chest wall pain of $Grade 2 after a median of
9 months (range: 0–24 months). This is in keeping with existing
data such as that reported by Andolino et al11 [median time to chest
wall toxicity 9 months (range: 1–50) months] and Welsh et al16
[median time to chest wall pain 6 months (range: 0–11 months)].
This study has limitations. Firstly, this was a retrospective review and
as such there are inherent problems with this method of data
collection. In addition, and as mentioned above, we did not have
sufﬁcient information to perform detailed analysis regarding patient-
related factors (e.g. comorbidities) which may contribute to the risk
of chest wall pain. Furthermore, the number of patients is relatively
small, as was the number of episodes of $Grade 2 chest wall pain.
Nonetheless, tumour size and the Dmax1 cm
3 were signiﬁcant pre-
dictors of$Grade 2 chest wall pain, and this information is clinically
useful in terms of attempting to avoid hot volumes in the chest wall,
particularly in patients with larger tumours. Our analysis was based
on two-dimensional tumour and target measurements, rather than
three-dimensional measurements such as GTV or the volume of
overlap between the PTV and the chest wall. The impact of these
three-dimensional factors on the development of chest wall pain
requires further investigation, although it is likely that maximum
tumour diameter (evaluated here) is closely correlated with tumour
volume, and that the distance from the tumour to the chest wall
(evaluated here) is closely correlated with the volume of PTVoverlap
with the chest wall. Despite these limitations, this analysis remains
worthwhile by contributing to the existing data regarding SABR-
associated chest wall pain, and providing a simple practical approach
to evaluating the risk of chest wall pain.
The advent of volumetric modulated arc treatment for lung SABR
has been shown to reduce chest wall doses,27 and this may result in
lower incidences of chest wall toxicity than have been observed with
static beam arrangements. Furthermore, new parameters to limit
chest wall toxicity may need to be deﬁned, given the changes in dose
distribution that occur with volumetric modulated arc treatment.
CONCLUSION
Grade 2 or greater chest wall pain is an infrequent side effect of
SABR treatment. For patients with tumours adjacent to the chest
wall who receive ﬁve-fraction SABR, increasing tumour size and
Dmax1 cm
3 were signiﬁcant predictors of $Grade 2 chest wall
pain. In an effort to reduce the risk of chest wall pain, it is
prudent to try to avoid hot volumes in the chest wall region,
particularly in patients with large tumours.
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